Related Experiment Videos
Aberrant FHIT transcripts in acute myeloid leukaemia
1Department of Internal Medicine, Kaohsiung Medical College Hospital, Taiwan.
British Journal of Haematology
|December 24, 1997
Summary
The fragile histidine triad (FHIT) gene shows abnormalities in many cancers. This study found aberrant FHIT transcripts in 27% of acute myeloid leukaemia patients, suggesting its role in myeloid carcinogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The FHIT gene, located at chromosome 3p14.2, is frequently altered in various cancers.
- Understanding the FHIT gene's role in hematological malignancies is crucial.
Purpose of the Study:
- To investigate the role of the FHIT gene in acute myeloid leukaemia (AML).
- To analyze FHIT gene expression and alterations in AML patients and cell lines.
Main Methods:
- Analysis of FHIT mRNA via reverse transcription PCR and sequencing.
- Evaluation of FHIT gene deletion using microsatellite polymorphism analysis.
- Study included 62 AML patients and 5 hematopoietic cell lines.
Main Results:
- Aberrant FHIT transcripts, lacking two or more exons, were found in 17/62 (27%) of AML patients.
- All tested hematopoietic cell lines exhibited aberrant FHIT transcripts.
- No loss of FHIT alleles was detected in the evaluated cases.
Conclusions:
- The FHIT gene alterations suggest a potential role in myeloid carcinogenesis.
- FHIT gene involvement may be linked to the late progression stages of AML.